Expert Interview
Discussing UCB's (Neurona Therapeutics) NRTX-1001 (Allogeneic Cell Therapy) for Drug-Resistant Epilepsy and the Phase 1/2 Data Presented at AAN 2026
Ticker(s): UCBJF, Neurona Therapeutics, NVS, ABT, JNJ, PFE, ESALF, JAZZ, SNYInstitution: Yale University
- Professor of Clinical Neurology and Interim director of Epilepsy Monitoring Unit at Yale Medical School
- Treats 500 adult patients with epilepsy and 600 patients with focal onset seizures per year
- Research interest in new therapies for epilepsy using anticonvulsant medications and devices to treat patients with refractory epilepsy, neuromodulation, surgical treatment of seizure disorders, invasive electroencephalogram (EEG) techniques, intracranial EEG, and intraoperative EEG mapping.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
